Načítá se...
High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma
BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4(+) lymphocytes and their prognostic impact in lung cancer. We hypot...
Uloženo v:
| Vydáno v: | J Thorac Dis |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6129889/ https://ncbi.nlm.nih.gov/pubmed/30233846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.45 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|